A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.
about
Patient-centered management of chemotherapy-induced nausea and vomitingRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewDelayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementImpact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life.Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyPrevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in ChinaEffect of virtual reality on time perception in patients receiving chemotherapyAcupuncture is underutilized in hospice and palliative medicine.Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and VomitingIntegrative review of factors related to the nursing diagnosis nausea during antineoplastic chemotherapy.Detection of Nausea-Like Response in Rats by Monitoring Facial Expression.Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients.Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review.Investigation of Nausea and Vomiting in Cancer Patients Undergoing ChemotherapyControlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.Antiemetic research: future directions.Patient-practitioner perception gap in treatment-induced nausea and vomiting.Antiemetic activity of volatile oil from Mentha spicata and Mentha × piperita in chemotherapy-induced nausea and vomitingRationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study.Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.[Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].[Incidence and management of chemotherapy-induced nausea and vomiting in women with breast cancer].2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting.Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting.Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster.Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study.
P2860
Q26828354-7809BB84-7670-46D1-82C9-6C285C275836Q28081186-661F16B8-48F6-412C-9830-B48EA600061EQ30235971-9D463CF9-2F86-40A4-8856-675525BEE57AQ30316569-DFE95276-B4D4-4EA3-AE12-AD201E7525FEQ34626554-4F4136F5-2520-4875-AA8F-8460C77E071FQ34638379-65B4DCF3-BACB-4C87-8AD3-63394C3A3ADEQ35345557-DF26B9FC-6EEC-406A-B813-7BE78DCD567CQ36222937-066313C8-B1D4-4AC1-9FE3-30695414C42DQ36897218-19B64F13-11A0-48E8-ABC8-4851F73A405EQ36905107-88F6FD2C-546D-4AE6-8307-65D6259F8740Q37186335-C4501050-61A4-4792-B95F-4373A99F2C12Q37326382-CF6C6B4B-CF26-44D7-80EE-435259652AECQ37347921-EB2729B5-51B1-42B7-9DB5-DE8EE07E9C63Q37574846-8446864D-0E55-4E3A-B3B3-E9EC543F00BBQ37669043-503A64BF-3B0E-47FE-8E06-EFA0F9D47AA2Q37735410-C55ACAED-34B1-4F7B-A7B4-4FBBE511CBD2Q37861640-874B7C53-B758-4BED-92B0-D7ABF22AB018Q38258166-F31794F4-3F3E-42C6-9596-889D050D44FDQ38646159-DA807D3B-865A-463B-A1BD-09560DBAF041Q38894275-44F4AAC9-D4B6-45FA-B2B4-C33CC85E416CQ38939984-705FC42A-AD67-4644-A3DB-DC2E41F30BCAQ39359365-10F0AF57-E0A9-4F66-9B23-7EDC3AF011D4Q39818791-EB18C75F-C683-469F-B6D0-D700DE3D5FFBQ40586658-E507E426-B98F-4A3D-BEDF-C55CC3CA0DEDQ41901188-CFE7E902-54C0-4F85-9211-FFFFAB1041B5Q43764003-61D29325-D373-4F64-97AC-D9A412401352Q44165565-5B57B483-6300-447F-95EF-D48588508F3AQ44339681-24BFFA8A-C89C-47A5-B362-AC3FDE00C68CQ44509416-E90B90FA-16EE-4603-A70A-67C12A46F867Q46355232-73CA938C-111C-40A8-9767-F43FA75FEB57Q46848063-8BA4E20C-EECC-4F45-B7F2-EA0E853C6800Q47572599-D14F06FB-2926-4A8E-8E10-00C26646C3D5Q47641840-7FDBC512-E68A-4BD0-8E41-51E5D9FDB3A8Q47664267-55F405F7-2035-40A0-87D3-169DE4C0168AQ48015419-25CD4DB3-FB18-4B62-9861-DA4AAD726938Q48218900-51FD3328-A896-4E71-9039-B1388B67BECCQ48281655-FF5CC84A-32E8-478E-AA43-A9165ADB3EA4Q48363175-D96FADDB-5859-48FB-A994-C880CA40F7B2Q48387907-B235714E-9A9F-4451-89F5-F5B0EF63869CQ51544100-7DAE2A13-9B34-43FF-8D43-7B19BCE91648
P2860
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A prospective observational st ...... ractice in a UK cancer centre.
@en
A prospective observational st ...... ractice in a UK cancer centre.
@nl
type
label
A prospective observational st ...... ractice in a UK cancer centre.
@en
A prospective observational st ...... ractice in a UK cancer centre.
@nl
prefLabel
A prospective observational st ...... ractice in a UK cancer centre.
@en
A prospective observational st ...... ractice in a UK cancer centre.
@nl
P2093
P50
P1476
A prospective observational st ...... ractice in a UK cancer centre.
@en
P2093
C Rittenberg
J Loncaster
M P Saunders
P2860
P2888
P304
P356
10.1007/S00520-007-0343-7
P577
2007-10-10T00:00:00Z
P6179
1052105626